These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23846932)

  • 1. Treatment of poorly differentiated neuroendocrine carcinoma of the pancreas.
    Gupta A; Duque M; Saif MW
    JOP; 2013 Jul; 14(4):381-3. PubMed ID: 23846932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.
    Hainsworth JD; Spigel DR; Litchy S; Greco FA
    J Clin Oncol; 2006 Aug; 24(22):3548-54. PubMed ID: 16877720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
    Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
    Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology.
    Crippa S; Partelli S; Belfiori G; Palucci M; Muffatti F; Adamenko O; Cardinali L; Doglioni C; Zamboni G; Falconi M
    World J Gastroenterol; 2016 Dec; 22(45):9944-9953. PubMed ID: 28018101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
    Rinke A; Gress TM
    Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
    Fazio N; Milione M
    Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site.
    Greco FA; Hainsworth JD
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-101-S19-105. PubMed ID: 9427278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Poorly-differentiated neuroendocrine carcinoma of ascending colon with liver metastases successfully treated with carboplatin and etoposide].
    Akiyama S; Niitani T; Narasaka T; Ohto T; Gamoh M
    Gan To Kagaku Ryoho; 2011 Jul; 38(7):1209-12. PubMed ID: 21772114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view.
    Fazio N; Spada F; Giovannini M
    Cancer Treat Rev; 2013 May; 39(3):270-4. PubMed ID: 22819619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Carboplatin and Etoposide Combination Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma: A Retrospective Case Series.
    Imai H; Shirota H; Okita A; Komine K; Saijo K; Takahashi M; Takahashi S; Takahashi M; Shimodaira H; Ishioka C
    Chemotherapy; 2016; 61(3):111-6. PubMed ID: 26636658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience.
    Olsen IH; Langer SW; Jepsen I; Assens M; Federspiel B; Hasselby JP; Hansen CP; Kjaer A; Knigge U
    Acta Oncol; 2012 Jan; 51(1):97-100. PubMed ID: 21615243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic neuroendocrine tumors: entering a new era.
    Oberstein PE; Remotti H; Saif MW; Libutti SK
    JOP; 2012 Mar; 13(2):169-73. PubMed ID: 22406593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers in neuroendocrine tumors.
    Duque M; Modlin IM; Gupta A; Saif MW
    JOP; 2013 Jul; 14(4):372-6. PubMed ID: 23846930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.
    Walter T; Tougeron D; Baudin E; Le Malicot K; Lecomte T; Malka D; Hentic O; Manfredi S; Bonnet I; Guimbaud R; Coriat R; Lepère C; Desauw C; Thirot-Bidault A; Dahan L; Roquin G; Aparicio T; Legoux JL; Lombard-Bohas C; Scoazec JY; Lepage C; Cadiot G;
    Eur J Cancer; 2017 Jul; 79():158-165. PubMed ID: 28501762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine tumours of the gastrointestinal tract: Chemotherapy.
    Arnold R; Rinke A; Schmidt Ch; Hofbauer L
    Best Pract Res Clin Gastroenterol; 2005 Aug; 19(4):649-56. PubMed ID: 16183533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas.
    Frizziero M; Spada F; Lamarca A; Kordatou Z; Barriuso J; Nuttall C; McNamara MG; Hubner RA; Mansoor W; Manoharan P; Fazio N; Valle JW
    Neuroendocrinology; 2019; 109(2):100-112. PubMed ID: 30703770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carcinoma of unknown primary site.
    Greco FA; Burris HA; Erland JB; Gray JR; Kalman LA; Schreeder MT; Hainsworth JD
    Cancer; 2000 Dec; 89(12):2655-60. PubMed ID: 11135228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated.
    Raj N; Valentino E; Capanu M; Tang LH; Basturk O; Untch BR; Allen PJ; Klimstra DS; Reidy-Lagunes D
    Pancreas; 2017 Mar; 46(3):296-301. PubMed ID: 27759713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3.
    Hentic O; Hammel P; Couvelard A; Rebours V; Zappa M; Palazzo M; Maire F; Goujon G; Gillet A; Lévy P; Ruszniewski P
    Endocr Relat Cancer; 2012 Dec; 19(6):751-7. PubMed ID: 22940375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma.
    Thomas KEH; Voros BA; Boudreaux JP; Thiagarajan R; Woltering EA; Ramirez RA
    Oncologist; 2019 Aug; 24(8):1076-1088. PubMed ID: 30635447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.